Immunoprofiling Reveals GATA3 as a Prognostic Marker in Transformed Mycosis Fungoides
The Journal of Dermatology · 2026
DOI: 10.1111/1346-8138.70070 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Bruno de Castro E Souza und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil. Hauptthemen laut MEDLINE: GATA3 Transcription Factor, Mycosis Fungoides, Skin Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundo de Apoio à Dermatologia de São Paulo (FUNADERSP).
Abstract (Originalsprache)
Transformed mycosis fungoides (TMF) is a rare, aggressive variant of cutaneous T‐cell lymphoma characterized by the presence of large neoplastic cells and poor clinical outcomes. A retrospective cohort of 22 TMF patients was analyzed using immunohistochemistry on formalin‐fixed, paraffin‐embedded (FFPE) tissue for GATA3 ( n = 20), T‐bet ( n = 22), and STAT3 ( n = 22). Expression was quantified by image analysis integrated optical density per total area (IOD/area), standardized by z ‐score and correlated with survival. Seventeen patients with complete data underwent unsupervised clustering ( k ‐means) and principal component analysis (PCA) based on marker expression profiles. High GATA3 expression was strongly associated with worse prognosis (median OS: 8.6 months vs. 41.7 months, p = 0.00094). T‐bet and STAT3 expressions showed no significant individual association with survival. Clustering analysis revealed three distinct immunoprofiles: (1) low expression of all markers (intermediate survival, 28.1 months), (2) high STAT3 and T‐bet expressions with intermediate GATA3 expression (longest survival, 53.1 months), and (3) high GATA3 expression with low STAT3 and T‐bet expressions (poorest survival, 9.5 months). GATA3 is a robust prognostic marker in TMF, identifying patients with particularly poor outcomes. Its elevated expression delineates a Th2‐skewed, immunosuppressive phenotype that may inhibit Th1/Th17 pathways via transcriptional repression. Integrative profiling reveals immunobiological subgroups with divergent prognoses, supporting GATA3 as a potential tool for risk stratification and a candidate for targeted intervention in TMF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil.
- Department of Pathology, University of São Paulo Medical School, São Paulo, Brazil.
ORCID-Profile: Bruno de Castro E Souza, Denis Miyashiro, Jade Cury-Martins, José Antonio Sanches
Förderung
- Fundo de Apoio à Dermatologia de São Paulo (FUNADERSP)
Zitieren
APA
Souza, B. C. E., Miyashiro, D., Cury-Martins, J., Valente, N. Y. S., da Silva, L. F. F., & Sanches, J. A. (2026). Immunoprofiling Reveals GATA3 as a Prognostic Marker in Transformed Mycosis Fungoides. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70070
Vancouver
Souza BCE, Miyashiro D, Cury-Martins J, Valente NYS, da Silva LFF, Sanches JA. Immunoprofiling Reveals GATA3 as a Prognostic Marker in Transformed Mycosis Fungoides. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70070
BibTeX
@article{Souza2026,
author = {Souza, Bruno de Castro E and Miyashiro, Denis and Cury-Martins, Jade and Valente, Neusa Yuriko Sakai and da Silva, Luiz Fernando Ferraz and Sanches, José Antonio},
title = {Immunoprofiling Reveals GATA3 as a Prognostic Marker in Transformed Mycosis Fungoides},
journal = {The Journal of Dermatology},
year = {2026},
doi = {10.1111/1346-8138.70070}
}
EUVIMED